Natus Sensory has acquired TheraB Medical Inc. for an undisclosed amount. TheraB Medical is a medical device company dedicated to advancing holistic jaundice treatment, enabling infants to remain with their mothers during therapy. Its flagship product, SnugLit, is a portable, wearable phototherapy garment designed to facilitate maternal-infant bonding and breastfeeding without interrupting treatment. TheraB Medical has been developing SnugLit in collaboration with over 300 nurses and mothers, with commercialization planned for the US and India in 2022.
This acquisition marks a strategic expansion for Natus Sensory, a company operating within the medical technology sector. By integrating TheraB Medical's innovative approach to neonatal care, Natus Sensory aims to enhance its portfolio of solutions for infant health. The SnugLit device represents a significant advancement in patient-centered care, aligning with broader trends towards less disruptive and more family-inclusive medical treatments.
The integration of TheraB Medical into Natus Sensory is expected to create substantial synergies. TheraB Medical stands to benefit from Natus Sensory's established infrastructure, resources, and market reach, accelerating the global commercialization and adoption of SnugLit. For Natus Sensory, the acquisition brings a unique, patented technology that addresses a critical need in neonatal jaundice management, strengthening its position in the medical device market and offering a differentiated product to healthcare providers and families.
Looking ahead, the combined entity is poised to make a greater impact on neonatal care worldwide. The acquisition is anticipated to accelerate the availability of SnugLit, improving access to a treatment that prioritizes both medical efficacy and the crucial bond between mother and infant. This strategic move underscores a commitment to innovation that supports comprehensive and compassionate patient care.